Parenteral Progestogen–Only

Warning

Progestogen (Parenteral)

Preferred list (P)

DEPO-PROVERA® injection

  • Medroxyprogesterone acetate 150mg/ml – intramuscular every 12 weeks

Total list (T)

SAYANA PRESS® injection

  • Medroxyprogesterone acetate 104mg/0.65ml – subcutaneous
  • Bioequivalent to intramuscular depot medroxyprogesterone acetate (IM DMPA, Depo-Provera®).
  • Administered at intervals of 13 weeks +/-7days.
  • Rates of loss of bone mineral density, amenorrhoea, weight gain and return to fertility similar to those seen with IM DMPA.
  • Sayana Press® may be preferable to IM DMPA in patients at risk of haematoma due to bleeding disorders or anticoagulation
  • For further information on side-effects, contraindications, method of administration please refer to the Faculty of Sexual and Reproductive Healthcare Clinical Guidance.

NEXPLANON® implant

NHSL Joint Adult Formulary Key

To indicate the category of a formulary medicine, updated sections adopt the following key:

Preferred list (P): First-line formulary choices.

Total list (T): Alternative choices when preferred list options not effective/not tolerated, or not indicated.

Specialist initiation (S1): Specialist initiation, or on the advice of a Consultant or Specialist Practitioner in this therapeutic area. Continuation in primary care is acceptable.

Specialist use only (S2): Supply via hospital, Homecare Service or a hospital based prescription (HBP) for dispensing by community pharmacy. Not prescribed in primary care setting.

Editorial Information

Last reviewed: 31/01/2022

Next review date: 31/01/2025

Author(s): NHSL.

Version: Please refer to the introduction section for an explanation of the review dates above.

Approved By: ADTC

Reviewer name(s): ADTC.